The $290 bln UK-based company will licence weight-loss drugs from China’s CSPC in a deal worth up to $18.5 bln. It’s the latest overseas giant drawn to the Asian country’s growing biotech prowess. But ...

CSPC Pharmaceutical Group and AstraZeneca have entered a global collaboration and licensing deal to co develop long acting ...

If you are wondering whether AstraZeneca shares are offering fair value at current levels, this breakdown will help you ...

How AstraZeneca’s recent performance may look to long term holders AstraZeneca (LSE:AZN) shares have moved mixed recently, with a 2.7% decline over the past day, a small gain over the past week, a 1.7 ...

Fintel reports that on January 27, 2026, Citigroup initiated coverage of AstraZeneca PLC - Depositary Receipt (NasdaqGS:AZN) ...

AstraZeneca has agreed a licensing deal worth up to $4.7bn with Chinese group CSPC Pharmaceuticals to develop weight-loss and ...

FTSE 100 Live 30 January: Gold retreats ahead of Fed choice, AstraZeneca strikes China deal - ...

AstraZeneca is to invest $15bn in China by the end of the decade, the UK drugs giant confirmed on Thursday, as part of the ...

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving ...

Under the deal, the FTSE 100 group will have the exclusive global rights, outside China, to CSPC's once-a-month jab that is ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.